EyePoint, Inc.: Key Takeaways from Our Investor Dinner with Mgmt Ahead of 1st Pivotal Readout in August in Wet AMD

Research evidence excerpt

EyePoint, Inc.: Key Takeaways from Our Investor Dinner with Mgmt Ahead of 1st Pivotal Readout in August in Wet AMD

ree rate, this is not a key regulatory or

commercial driver, and EyePoint added that treatment burden reduction matters more. It

stressed the importance of contextualizing the rescue-free rate, posing the question “Is

50% rescue-free worse than 75% rescue-free?” to the group and answering that you

cannot know until you know how many rescue injections those patients got (i.e., the

interpretability hinges on how many supplemental injections that rescued patient

receives). For instance, if 50% of patients get rescued, but only received one rescue

injection, that would be considered an “outstanding” result.

• On the inclusion of treatment-naïve patients. With a largely treatment-naïve

population (~76%), more stringent rescue criteria vs DAVIO 2 (e.g., no longer permitting

physicians to deliver supplemental anti-VEGF injections at their own clinical discretion),

and the reinjection of Duravyu at 6mo, it is expected that there will be fewer rescues,

which should translate to a strong reduction in treatment burden, and mgmt remains

convinced that the treatment-naïve patients should do better than previously-treated

patients.

• On safety. EyePoint continues to be very comfortable on the safety profile. EyePoint last

saw the masked safety data from both trials in May; at that point, all of the active patients

in the treatment arm had received their second Duravyu at Week 32 and over 35% had also

received their third planned dose at Week 56; mgmt emphasized that most ocular AEs /

SAEs occur around the time of injection, making the post-second-dose safety look

important because the second Duravyu injection is the last one before the primary

endpoint.